Evaluation of Aflibercept and Ziv-Aflibercept Binding Affinity to Vascular Endothelial Growth Factor, Stability, and Sterility after Compounding

被引：0
|
作者：
Farah, Julia Lima [1 ]
Sano, Ronaldo Yuiti [1 ]
Longo Maugeri, Ieda Maria [2 ]
Teixeira, Daniela [2 ]
Ishimura, Mayari Eika [2 ]
Martins, Gabriela [2 ]
Mimica, Lycia [3 ]
Silva, Cely [3 ]
Meyer, Carsten [2 ]
de Oliveira Dias, Joao Rafael [2 ]
Andrade, Gabriel Costa [2 ]
Farah, Michel Eid [2 ]
机构：
[1] Santa Casa Sao Paulo, Ophthalmol, Sao Paulo, Brazil
[2] Univ Fed Sao Paulo, Paulista Sch Med, Sao Paulo, Brazil
[3] Santa Casa Sao Paulo, Sao Paulo, Brazil
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2018年 / 59卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
1452
引用
收藏
页数：7
相关论文
共 50 条
  • [1] Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
    De Lima Farah J.
    Sano R.
    Maugéri I.M.L.
    Teixeira D.
    Ishimura M.E.
    Martins G.
    Mimica L.M.J.
    Da Silva C.B.
    Meyer C.H.
    De Oliveira Dias J.R.
    De Andrade G.C.
    Farah M.E.
    [J]. International Journal of Retina and Vitreous, 4 (1)
  • [2] The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration
    Jakkrit Juhong
    Pear Ferreira Pongsachareonnont
    Thanapong Somkijrungroj
    Apivat Mavichak
    Adisai Varadisai
    Pajaree Chariyavilaskul
    Tanittha Chatsuwan
    Thitima Benjachat Suttichet
    Kittisak Kulvichit
    [J]. Scientific Reports, 12
  • [3] The sterility, stability and efficacy of repackaged ziv-aflibercept for intravitreal administration
    Juhong, Jakkrit
    Pongsachareonnont, Pear Ferreira
    Somkijrungroj, Thanapong
    Mavichak, Apivat
    Varadisai, Adisai
    Chariyavilaskul, Pajaree
    Chatsuwan, Tanittha
    Suttichet, Thitima Benjachat
    Kulvichit, Kittisak
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy
    Anshuman, Kumar
    Ratra, Dhanashree
    [J]. INDIAN JOURNAL OF OPHTHALMOLOGY, 2019, 67 (07) : 1119 - 1120
  • [5] Ziv-aflibercept: A cost-effective, off-label, highly potent antagonist of vascular endothelial growth factor
    Mansour, Ahmad M.
    Stewart, Michael W.
    Farah, Michel E.
    Mansour, Hana A.
    Chhablani, Jay
    [J]. ACTA OPHTHALMOLOGICA, 2020, 98 (05) : E540 - E548
  • [6] Analysis of the binding affinity of vascular endothelial growth factor A (VEGF) to ranibizumab, aflibercept and bevacizumab
    Wang, Xiangdan
    Yang, Jihong
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [7] Intraocular Pharmacokinetics of Aflibercept and Vascular Endothelial Growth Factor-A
    Celik, Nil
    Scheuerle, Alexander
    Auffarth, Gerd U.
    Kopitz, Juergen
    Dithmar, Stefan
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (09) : 5574 - 5578
  • [8] Aflibercept - Antiangiogenic agent vascular endothelial growth factor inhibitor
    Sorbera, L. A.
    [J]. DRUGS OF THE FUTURE, 2007, 32 (02) : 109 - 117
  • [9] CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
    de Oliveira Dias, Joao Rafael
    de Andrade, Gabriel Costa
    Kniggendorf, Vinicius Ferreira
    Novais, Eduardo Amorim
    Maia, Andre
    Meyer, Carsten
    Watanabe, Sung Eun Song
    Farah, Michel Eid
    Rodrigues, Eduardo Buschele
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (08): : 1499 - 1507
  • [10] Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration
    Sawada, Tomoko
    Wang, Xiying
    Sawada, Osamu
    Saishin, Yoshitsugu
    Ohji, Masahito
    [J]. CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2018, 46 (01): : 46 - 53
12345